Redoxis

What Redoxis does

Redoxis AB is a privately held preclinical contract research organization headquartered at Medicon Village in Lund, Sweden. Founded in 2007 as a spinout rooted in Medical Inflammation Research and fully dedicated to CRO services since 2016, the company provides fee-for-service efficacy evaluation, mechanism-of-action studies, and biomarker characterization for biotech and pharmaceutical clients developing therapeutics in inflammation and autoimmune disease. Its offering is structured around three integrated service pillars — In Vitro & Ex Vivo Services (flow cytometry, cytokine profiling, gene expression, primary cell assays), In Vivo Services (validated rodent disease models spanning rheumatoid arthritis, multiple sclerosis/EAE, inflammatory bowel disease, psoriasis, SLE, atherosclerosis, anti-GBM nephritis, Guillain-Barré/EAN, Parkinson's, and acute inflammation/sepsis), and High-Resolution Biology (quantitative histopathology, IHC/IF, multiplex tissue staining, digital slide scanning, scRNA-seq, and bioinformatic analysis).

The underlying technology stack combines an extensive portfolio of well-characterized in vivo models (including rare platforms such as Mannan-Induced Psoriatic Arthritis in SKG mice and specialized microglia/CNS and macrophage polarization assays) with advanced analytical readouts — Luminex multiplex cytokine analysis, ELISA, FluoroSpot/ELISpot, qPCR/ddPCR, bulk and single-cell RNA-seq with pathway enrichment, Western blot, and CatWalk XT automated gait analysis for functional endpoints. A BSL-2 certified facility supports in vivo characterization of advanced therapy medicinal products (gene, cell, and mRNA therapies), and a 2026 expansion of histology/imaging capacity via the ImaGene-iT acquisition extends the integrated tissue analysis offering.

Redoxis operates a project-based, quote-driven revenue model with no publicly disclosed pricing, generating revenue through study contracts priced by model complexity, species, readouts, and timelines. Go-to-market is consultative and relationship-driven: the CEO, COO, and scientific leads personally engage enterprise pharma and biotech clients (named logos include LEO Pharma, Chiesi, EDO GmbH, IBC Generium, Indus Biotech, Rewind Therapeutics, BCI Pharma, Lipum, Aqilion, Euroscreen, Glucox Biotech, and others) supported by conference presence at BIO-Europe Spring and Nordic Life Science Days, content-driven website and blog, LinkedIn activity, and newsletter distribution. All services are delivered from Lund; international clients are served via direct scientific engagement with the management team. Recent strategic moves include the March 2026 ImaGene-iT histology acquisition, CatWalk XT gait analysis launch, ATMP characterization service introduction, and partnerships with RG Discovery (bioanalytical/PK-PD) and the Örebro University TMAO consortium.

Name

Redoxis

Legal name

Redoxis AB

Website

https://redoxis.se

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Redoxis is a privately held preclinical CRO in Lund, Sweden, providing fee-for-service in vivo, ex vivo, and high-resolution biology studies for biotech and pharma clients developing inflammation and autoimmune therapeutics.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical CRO services
• Inflammation disease models
• Autoimmune disease research
• In vivo efficacy studies
• Translational immunology assays

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services (CRO): Redoxis operates as a preclinical contract research organization providing fee-for-service research studies to biotech and pharmaceutical companies. Services are project-based, with studies designed around specific therapeutic modalities and development phases. Revenue is generated through study contracts, with pricing based on study complexity, models used, and readouts required.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Redoxis is a specialized preclinical contract research organization (CRO) providing fee-for-service research studies to biotech and pharmaceutical companies. The company offers an integrated portfolio of in vitro, ex vivo, and in vivo services focused on inflammation and autoimmune disease, including disease models (rheumatoid arthritis, multiple sclerosis, IBD, psoriasis, SLE, Parkinson's), flow cytometry, cytokine profiling, histopathology, and single-cell transcriptomics. All studies are designed around the client's therapeutic modality and development phase, executed from Redoxis's BSL-2 certified laboratories in Lund, Sweden.

Product overview

Redoxis is a specialized preclinical contract research organization (CRO) offering an integrated portfolio of in vitro, ex vivo, and in vivo services focused on inflammation and autoimmune disease research. The core offering comprises three interconnected service pillars: In Vitro & Ex Vivo Services (flow cytometry, cytokine profiling, gene expression, primary cell assays); In Vivo Services (disease models including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, SLE, Parkinson's, GBS, atherosclerosis, and acute inflammation); and High-Resolution Biology (quantitative histopathology, advanced imaging, and single-cell transcriptomics). These services are designed to work together, enabling clients to move from cellular mechanism studies through in vivo efficacy testing to tissue-level validation within a single CRO partner. Specialized sub-services include B and T cell biology platforms, macrophage/microglia assays, reporter gene systems, molecular biomarker applications, pharmacokinetics/PD services, and ATMP characterization for advanced therapeutic modalities.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vitro & Ex Vivo Services Laboratory-based immune function assays for biotech and pharmaceutical clients exploring cellular phenotypes in controlled systems. Includes flow cytometry, cytokine profiling, gene expression analysis, and primary cell-based assays designed around therapeutic modality and development phase.
• In Vivo Services Preclinical in vivo disease model studies for efficacy evaluation in inflammation and autoimmune conditions in rodents. Includes models of rheumatoid arthritis, multiple sclerosis, IBD, psoriasis, SLE, Parkinson's, atherosclerosis, GBS, atopic dermatitis, and acute inflammation.
• High-Resolution Biology Advanced tissue analysis combining quantitative histopathology, immunohistochemistry, immunofluorescence, multiplex tissue staining, digital slide scanning, single-cell RNA sequencing, and bioinformatic pathway analysis for multidimensional, translationally relevant data.
• Acute Inflammation and Sepsis Models In vivo rodent models inducing rapid, reproducible immune activation using LPS, R848, or anti-CD3 antibody for studying cytokine dynamics and innate immune responses.
• Anti-GBM Nephritis Model Mouse model of immune-mediated glomerulonephritis induced by anti-GBM antibody injection, mimicking rapidly progressive glomerulonephritis and Goodpasture's syndrome.
• Atherosclerosis Models In vivo atherosclerosis models using ApoE-deficient and LDLr-deficient mice recapitulating key aspects of human cardiovascular disease for evaluating anti-inflammatory and lipid-lowering therapies.
• Atopic Dermatitis Models Murine atopic dermatitis models (oxazolone-induced and MC903-induced) replicating skin inflammation, epidermal hyperplasia, and elevated IgE for evaluating topical and systemic treatments.
• Guillain-Barré Syndrome (EAN) Model Experimental Autoimmune Neuritis (EAN) model in rats induced by immunization with myelin peptides, recapitulating peripheral nerve inflammation, demyelination, and ascending paralysis.
• Inflammatory Bowel Disease Models Colitis models including DSS-induced, TNBS-induced, oxazolone-induced, and adoptive T cell transfer models for evaluating immunomodulatory therapies and anti-inflammatory compounds.
• Multiple Sclerosis (EAE) Models Experimental Autoimmune Encephalomyelitis (EAE) models in rats and mice using various immunogens (SCH, MOG, MBP, PLP) to study MS-like disease with different immune mechanisms and relapse profiles.
• Parkinson's Disease Models Neurotoxin-based Parkinson's models (6-OHDA in rats, MPTP in mice) for studying dopaminergic cell loss, neuroinflammation, and evaluating neuroprotective therapies.
• Psoriasis and Psoriatic Arthritis Models Imiquimod-induced psoriasis model and Mannan-induced psoriatic arthritis (MIP) model in SKG mice for evaluating therapeutic strategies targeting cytokine signaling and T cell activity.
• Rheumatoid Arthritis Models Comprehensive portfolio of RA models including CIA (mouse and rat), CAIA, G6PI-induced, PIA, and adoptive T cell transfer models for evaluating anti-inflammatory and disease-modifying agents.
• Systemic Lupus Erythematosus (SLE) Models SLE models including Pristane-Induced Lupus, NZB/W F1 Spontaneous Lupus, and MRL/lpr Spontaneous Lupus reflecting different aspects of autoimmune systemic disease.
• CatWalk XT Automated Gait Analysis Operator-independent functional readout service using the CatWalk XT system to capture highly sensitive gait parameters for preclinical studies in neuroinflammation, pain, arthritis, and peripheral neuropathy models.
• Histology and Immunohistochemistry Capacity Expanded histology and immunohistochemistry services including quantitative tissue evaluation, digital imaging analysis, H&E and special stainings, IHC, IF, and multiplex tissue staining closely integrated with in vivo and in vitro platforms.

Quantifiable outcome

• Customer testimonials consistently reference high-quality, reproducible data and professional study execution

Named customers17 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eight partnerships are on record, tiered core, strategic, minor and supporting.

• Noldus Information TechnologycoreTechnology or Integration · 19 March 2026Redoxis invested in the CatWalk XT automated gait analysis system from Noldus Information Technology. CatWalk XT enables highly sensitive and objective gait parameters for preclinical research in neuroinflammation, pain, arthritis, and peripheral neuropathy models, complementing established clinical scoring and histopathology endpoints.
• ImaGene-iTcoreTechnology or Integration · 9 March 2026Redoxis acquired histology equipment and expanded capacity from ImaGene-iT. As part of this transition, founders Anders Brinte and Bo Holmqvist will remain involved as consultants ensuring knowledge transfer and continuity. Hanna Wallin joined Redoxis bringing extensive histology and tissue analysis experience. This investment strengthens integrated tissue analysis closely connected to Redoxis' in vivo, ex vivo, and in vitro platforms.
• Örebro UniversitystrategicStrategic or Co-development Partner · 1 January 2025Redoxis is an industry partner in a SEK 24 million research consortium led by Örebro University exploring the role of TMAO (trimethylamine N-oxide) in chronic diseases (cardiovascular disease, chronic kidney disease, periodontitis). Project runs 2025-2030 and includes clinical experts from Region Örebro län, Karolinska Institutet, and international collaborators from University of Lincoln, University of Glasgow, and Temple University.
• RG DiscoverycoreStrategic or Co-development PartnerCollaboration with RG Discovery for bioanalytical method development and sample analysis. RG Discovery brings extensive experience in bioanalytical services supporting pharmacokinetic (PK) and pharmacodynamic (PD) studies. This partnership enables seamless workflow from sample collection to validated bioanalytical results, integrating with Redoxis' in vivo efficacy models.
• Bio-Rad LaboratoriesminorStrategic or Co-development PartnerIndustry partner in the TMAO research consortium contributing expertise and resources to the interdisciplinary project on diet-metabolite-chronic disease relationships.
• QIAGENminorStrategic or Co-development PartnerIndustry partner in the TMAO research consortium providing molecular biology expertise and resources for the project.
• Probi ABminorStrategic or Co-development PartnerIndustry partner in the TMAO research consortium focused on gut microbiome and chronic disease research.
• Academic Core FacilitiessupportingTechnology or IntegrationAccess to advanced sorting instruments (FACSAria III, FACSMelody, FACSymphony S6, FACSDiscover S8) via academic core facilities for high-purity cell isolation when in-house capabilities are insufficient.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Porsolt: French preclinical CRO focused on efficacy and safety pharmacology models across inflammation, CNS, and metabolic disease, with a similar specialty-CRO profile and comparable size to Redoxis.
• MD Biosciences: Preclinical CRO with strong inflammation and immunology focus offering in vivo efficacy, histology, and biomarker services for autoimmune and inflammatory indications, directly comparable to Redoxis' therapeutic specialization.
• Crown Bioscience: Larger preclinical CRO offering in vivo efficacy models across oncology, inflammation, and metabolic disease with integrated biomarker and translational biology platforms — overlapping directly with Redoxis' service menu at greater scale.
• Bolder BioPATH: US-based preclinical CRO specializing in inflammatory and autoimmune disease models, particularly rheumatoid arthritis, with in vivo efficacy, histopathology, and biomarker services closely aligned with Redoxis' core offering.

Broad incumbents

• Inotiv: US-listed preclinical CRO and research models provider offering in vivo efficacy, toxicology, and pathology services, including inflammation and autoimmune models — broader and larger than Redoxis but overlapping in core preclinical capabilities.
• WuXi AppTec: Global CRO/CDMO with extensive preclinical in vivo and in vitro capabilities across multiple therapeutic areas, including immunology and inflammation models, competing for the same enterprise biotech and pharma preclinical outsourcing budgets as Redoxis.
• Charles River Laboratories: Global preclinical CRO leader providing in vivo efficacy, safety assessment, and research models across all major therapeutic areas, including established autoimmune and inflammation franchises that compete directly with Redoxis for biotech and pharma contracts.
• Evotec: Large discovery and preclinical CRO offering integrated in vitro and in vivo services across multiple therapeutic areas, including immunology, with a broader platform and partnership-based revenue model that competes for similar biotech customers.

Regional players

• Oncodesign: French preclinical CRO with strength in inflammation, fibrosis, and immuno-oncology drug discovery, providing comparable in vivo efficacy and translational services to a European biotech/pharma customer base similar to Redoxis' clients.

Emerging players

• InnoSer: European preclinical CRO offering in vivo efficacy and safety studies with focus on neurological, metabolic, and inflammatory disease models, comparable in size and therapeutic breadth to Redoxis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/redoxis-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redoxis